Levodopa/Carbidopa Teva (Carbidopa, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine by aromatic L‑amino acid decarboxylase. This increase in central dopamine compensates for the deficiency seen in Parkinson's disease, restoring more normal movement control.

The exact dose of Levodopa/Carbidopa Teva is determined by the prescribing clinician based on the patient’s disease stage, response, and tolerance. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions precisely.

Safety data for Levodopa/Carbidopa in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for Parkinson’s disease because it directly restores dopamine. Other classes, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or early‑stage options but generally provide less robust motor improvement.

Store Levodopa/Carbidopa Teva at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Levodopa/Carbidopa Teva is taken orally, usually with a glass of water. It may be taken with or without food, but high‑protein meals can interfere with absorption, so spacing the dose from protein‑rich meals is often recommended.

Serious risks include severe orthostatic hypotension, neuroleptic malignant syndrome, and psychiatric complications such as hallucinations or severe depression. Patients should be monitored closely for these events, especially during dose adjustments.

Individuals with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in patients taking non‑selective MAO inhibitors due to the risk of hypertensive crisis, and caution is advised in those with severe cardiovascular or hepatic disease.